Extracorporeal Carbon Dioxide Removal in Severe Chronic Obstructive Pulmonary Disease Exacerbation

NCT03692117 | Unknown

• 1 other identifier: 2016YFC1304304-4
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The conventional treatment for Severe acute exacerbation of Chronic obstructive pulmonary disease including noninvasive respiratory support, invasive respiratory support, etc, but there are many kinds of limitations and complications. Extracorporeal Carbon Dioxide Removal is a life support technology, which can effectively remove CO2. Recently some clinical studies have showed that ECCO2R can effectively improve the AECOPD patient's respiratory failure, avoid intubation and removal of endotracheal intubation. We performed a study to evaluate the clinical effectiveness of ECCO2R in the treatment of AECOPD patients.

Conditions

COPD Exacerbation

Keywords

COPD Exacerbation; Severe; ECCO2R; invasive mechanical ventilation

Outcome Measures

Primary Outcomes (1)

• incidence of avoid endotracheal intubation

  avoid endotracheal intubation and Invasive mechanical ventilation

  30days

Interventions

Extracorporeal Carbon Dioxide Removal DEVICE

Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patients with AECOPD accept the NPPV treatment, deterioration or no improvement of Clinical status. we expected them to be avoided endotracheal intubation after treatment with ECCO2R

You may qualify if:

• NPPV treatment failure:
• deterioration or no improvement after treatment with NPPV, pH \< 7.25, PaCO2 \> 70mmHg
• Obvious respiratory distress, RR \> 30 times/min
• Breathing extreme fatigue

You may not qualify if:

• Older than 75 years
• endotracheal intubation or tracheostomy
• obviously a lot of pus yellow phlegm, expectorate difficult
• Chest CT: obviously a wide range of consolidation
• BMI \< 20 kg/m2,
• Dysfunction of other organ of extrapulmonary
• serious hemodynamic instability
• severe hypoxemia, PaO2 / FiO2 \< 100mmHg
• home noninvasive positive pressure ventilation for a long time
• lung fungal infection
• contraindication of anticoagulation
• Platelet \< 80000 per cubic millimeter
• Serum creatinine \> 200 umol/L
• cardiac arrest
• Hospice care

Sponsors & Collaborators

• China-Japan Friendship Hospital: lead

Study Sites (1)

China-Japan Friendship hospital

Beijing, Beijing Municipality, 100028, China

RECRUITING

MeSH Terms

Conditions

Lymphoma, Follicular

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Qingyuan Zhan, M.D.

  China-Japan Friendship Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Min Li, Master

CONTACT

13683598417; qlyy_limin@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: head of Pulmonary and Critical care medicine ward 4

Study Record Dates

• First Submitted: September 25, 2018
• First Posted: October 2, 2018
• Study Start: January 1, 2017
• Primary Completion: December 1, 2020
• Study Completion: December 1, 2020
• Last Updated: January 18, 2020

Record last verified: 2020-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)